World Trade Tianjie Pharmaceuticals

World Trade Tianjie Pharmaceuticals is a Chinese biotechnology company specializing in the development and commercialization of oncolytic virus therapies. The company is most notable for Oncorine (H101), which in 2005 became the first oncolytic virus drug approved by any regulatory authority globally, specifically for the treatment of nasopharyngeal carcinoma in China. World Trade Tianjie focuses on leveraging recombinant viral technology to create targeted cancer treatments that selectively replicate in and destroy tumor cells. The company maintains significant research and manufacturing operations in Beijing and Hainan, and it operates through its key subsidiary, Shanghai Sunway Biotech. Its pioneering work has established it as a historical leader in the Chinese gene therapy and oncology sectors.